Dyslipidemia

A secondary analysis of the AFIRE trial provides further detail on the reduction in event risk and mortality associated with rivaroxaban monotherapy compared to combination therapy in patients with atrial fibrillation and stable coronary artery disease.

Drs Paul S. Jellinger, Erin D. Michos, Matthew J. Budoff, Christie Ballantyne, and Yehuda Handelsman share closing thoughts and advice for the management of ASCVD and hypercholesterolemia.

Experts in endocrinology and cardiology review novel agents in the pipeline for the management of hypercholesterolemia and ASCVD.

Erin D. Michos, MD, MHS, leads a discussion on selecting the appropriate patient populations for the use of bempedoic acid when managing atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia.

Christie Ballantyne, MD, leads a discussion on the use of bempedoic acid for the management of atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia as seen in the CLEAR studies.

Erin D. Michos, MD, MHS; Christie Ballantyne, MD; Yehuda Handelsman, MD; and Paul S. Jellinger, MD, MACE, address the use of combination therapies and statin intolerance in patients with atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia.

A post hoc analysis of the AUGUSTUS trial provides an overview of the effects of various antithrombotic regimens after ACS or PCI in patients with AFib and a history of stroke, TIA, or thromboembolism.

Matthew J. Budoff, MD; Paul S. Jellinger, MD, MACE; Erin D. Michos, MD, MHS; Yehuda Handelsman, MD; and Christie Ballantyne, MD, comment on the use of icosapent ethyl in reducing atherosclerotic cardiovascular disease (ASCVD) events and managing lipid disorders.

Health care experts discuss use of older agents to control atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia in certain patient populations.

An analysis of data from the Fuwai PCI registry details the incidence of adverse events and risk of bleeding associated with clopidogrel monotherapy versus aspirin monotherapy 12 months post-PCI in high-risk patients.

Christie Ballantyne, MD, leads a discussion on the efficacy and safety of bempedoic acid for the management of ASCVD and hypercholesterolemia.

Matthew J. Budoff, MD; Erin D. Michos, MD, MHS; and Paul S. Jellinger, MD, MACE, discuss the role of statins, ezetimibe, and PSCK9 inhibitors for patients with ASCVD and hypercholesterolemia.

Christie Ballantyne, MD, and Erin D. Michos, MD, MHS, explore the impact of lifestyle changes on managing ASCVD and hypercholesterolemia.

Expert endocrinologists and cardiologists review the role of DCRM multispecialty practice recommendations and the use of combination therapy for patients with ASCVD and hypercholesterolemia.

Drs Erin D. Michos, Matthew J. Budoff, Paul S. Jellinger, and Yehuda Handelsman, share their approach to incorporating guideline recommendations for the management of patients with ASCVD and hypercholesterolemia in clinical practice.

Dr Christie Ballantyne leads a discussion on how the management of patients with ASCVD and hypercholesterolemia has changed over the years.

Each weight-loss regimen had similar success in obesity management, regardless of patients reducing their calorie consumption through time-restricted eating or through calorie restriction alone.

Yehuda Handelsman, MD; Christie Ballantyne, MD; Paul S. Jellinger, MD, MACE; and Erin D. Michos, MD, MHS, comment on the impact of diabetes on chronic kidney disease and cardiovascular disease.

Matthew J. Budoff, MD; Christie Ballantyne, MD; and Paul S. Jellinger, MD, MACE, discuss the incidence and prevalence of atherosclerotic cardiovascular diseases (ASCVD) associated with hypercholesterolemia and risk factors for disease.

No evidence of lower Lp(a)-associated risks in hormone therapy users versus nonusers was observed.

Data from a phase 2b trial of bentracimab presented by Deepak Bhatt, MD, MPH, at ACC.22 demonstrates it the ability for reversing antiplatelet effects in an older population.

Viet Le, PA-C, provides perspective on an ACC.22 study examining long-term risk of MACE based on alcohol consumption and whether or not the patient had a history of statin use.

An analysis of data from more than 110k hospitalized patients with COVID-19 suggests aspirin use on the first day of hospitalization was linked to lower odds for both in-hospital mortality and pulmonary embolism in weighted analyses.

Data from the REMAP-CAP trial suggests use of aspirin or P2Y12 inhibitors had a low likelihood of improving organ support-free days in critically ill patients with COVID-19 within 21 days compared to no antiplatelet therapy.